Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Novo Nordisk A/S
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07023029CT.gov A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants | — | Completed | — | — | — |
NCT06612268CT.gov A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | — | Recruiting | — | — | — |
NCT06609226CT.gov A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia | — | Recruiting | — | — | — |
NCT06581627CT.gov A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants | — | Completed | — | — | — |
NCT05725902CT.gov Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease | — | Completed | — | — | — |
NCT05953584CT.gov A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke | — | Recruiting | — | — | — |
NCT06198712CT.gov A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease | — | Recruiting | — | — | — |
NCT04987489CT.gov A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease | — | Completed | — | — | — |
NCT04624659CT.gov A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS) | — | Active Not Recruiting | — | — | — |
NCT03815695CT.gov A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sickle Cell Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Etavopivat (this asset) | Novo Nordisk A/S | P3 | B · 60 |
| Glutamine | Ain Shams University | P4 | BBB |
| Hydroxyurea | St. Jude Children's Research Hospital | P4 | BB |
| Magnesium Metallicum | Medical College of Wisconsin | P3 | BB |
| Crizanlizumab | Novartis Pharmaceuticals | P4 | BB |
| Nivestim | St. Jude Children's Research Hospital | P4 | BB |
| ARG | Tanta University | P3 | BB |
| Fentanyl | University College Dublin | P4 | BB |
| Nepenthe | Oman Medical Speciality Board | P4 | BB |
+42 more in the Sickle Cell Disease cohort
Other indications for Etavopivat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Thalassemia | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Etavopivat in Sickle Cell Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/etavopivat-sickle-cell-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →